GlaxoSmithKline, Apotex Sue Lupin Over Generic Paxil Drug

Updated on

A unit of GlaxoSmithKline Plc, the U.K.’s largest drugmaker, joined with Canadian business partner Apotex Inc. to sue Indian generic pharmaceutical firm Lupin Ltd. over plans to market copies of the antidepressant Paxil.

SmithKline Beecham Ltd. claims Lupin is infringing a U.S. patent for Paxil and should pay damages if the generic product is brought to market, according to a complaint filed Monday in federal court in Wilmington, Delaware.

Lupin executives are making “substantial preparation in the U.S.” to sell the copies, which indicates “a refusal to change the course of their actions,” according to the complaint.

Shamsher Gorawara, a spokesman for Lupin, India’s second-largest drugmaker by market value, declined to comment on the lawsuit.

The case is Apotex v. Lupin, 15-cv-357, U.S. District Court, District of Delaware (Wilmington).

(Updates with company response in fourth paragraph.)
    Before it's here, it's on the Bloomberg Terminal. LEARN MORE